Analyzed interventions and the estimates used for the stage were interventions are applied to.

aCase Fatality - Estimates for stages III and IV are from Groot et al. [7] and for stages I and II from Zelle et al. [22]. The CFs for the untreated patients are from Groot et al. [7] and were corrected based on Bloom et al [57].
bDisability Weights - Estimates from Zelle et al.[22].
cCurrent stage distribution CR is based on Ortiz [24]; MX onKnaul et al. [17]; Effects of MAR derived from Devi [50]; Effects of screening interventions were based on stage shifts from baseline Groot et al.[7] to the stage distribution USA in Bland et al. [58]. Stage shifts were adapted by calculating relative differences in detection rates between the USA and CR/MX from Duffy & Gabe [59]. Calculations included age-specific incidence (MoH CR & Unidad Analysis Económica MX), prevalence (WHO 2008), sojourn time Duffy & Gabe [59], sensitivity Bobo et al. [60] and attendance rates (75% in the USA vs. 80% in Costa Rica and Mexico).
dWe assumed in Mexico implementing MAR could not lead to a higher proportion of stage IV patients and increase stage III with the difference of 0.6%.